Caris Life Sciences, Inc. (BMV:CAI)
| Market Cap | 96.07B -22.4% |
| Revenue (ttm) | 18.89B +61.5% |
| Net Income | 1.73B |
| EPS | 6.38 |
| Shares Out | n/a |
| PE Ratio | 49.65 |
| Forward PE | 68.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47 |
| Open | 317.00 |
| Previous Close | 493.00 |
| Day's Range | 317.00 - 317.00 |
| 52-Week Range | 317.00 - 493.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Caris Life Sciences
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecula... [Read more]
Financial Performance
In 2025, Caris Life Sciences's revenue was $812.03 million, an increase of 96.97% compared to the previous year's $412.26 million. Losses were -$537.96 million, 42.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
Caris Life Sciences price target raised to $25 from $22 at Piper Sandler
Piper Sandler raised the firm’s price target on Caris Life Sciences (CAI) to $25 from $22 and keeps a Neutral rating on the shares. The firm is updating its estimates…
Caris Life Sciences price target raised to $36 from $28 at Citi
Citi raised the firm’s price target on Caris Life Sciences (CAI) to $36 from $28 and keeps a Buy rating on the shares.
Caris Life Sciences price target raised to $38 from $36 at TD Cowen
TD Cowen raised the firm’s price target on Caris Life Sciences (CAI) to $38 from $36 and keeps a Buy rating on the shares. The firm said while they have…
Caris Life Sciences price target raised to $33 from $32 at Baird
Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Caris Life Sciences (CAI) to $33 from $32 and keeps an Outperform rating on the shares. The firm updated…
Caris Life Sciences Earnings Call Transcript: Q3 2026
Q3 revenue rose 27% and clinical volume grew 21%, with growth accelerating for a second quarter. FY revenue guidance increased to $1.04B-$1.05B as monitoring and MRD launches broaden the portfolio.
Caris Life Sciences Earnings release: Q3 2026
Caris Life Sciences released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Caris Life Sciences Quarterly report: Q3 2026
Caris Life Sciences has published its Q3 2026 quarterly earnings report on November 4, 2026.
Caris Life Sciences Slides: Q3 2026
Caris Life Sciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Caris Life Sciences reports Q3 EPS 5c, consensus 2c
Reports Q3 revenue $275.4B, consensus $255.34M. “This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year,” said David Dean Halbert, CEO. “Every case we run…
Caris Life Sciences now sees 2026 revenue $1.04B-$1.05B, consensus $1.03B
16:09 EST Caris Life Sciences (CAI) now sees 2026 revenue $1.04B-$1.05B, consensus $1.03B
Caris Life Sciences price target raised to $38 from $33 at BTIG
BTIG raised the firm’s price target on Caris Life Sciences (CAI) to $38 from $33 and keeps a Buy rating on the shares as part of a broader research note…
Caris Life Sciences price target raised to $30 from $22 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on Caris Life Sciences (CAI) to $30 from $22 and keeps a Hold rating on the shares. The firm updated its…
Caris Life Sciences price target raised to $35 from $25 at JPMorgan
JPMorgan analyst Casey Woodring raised the firm’s price target on Caris Life Sciences (CAI) to $35 from $25 and keeps an Overweight rating on the shares. The firm updated models…
Caris Life Sciences price target raised to $36 from $30 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Caris Life Sciences (CAI) to $36 from $30 and keeps a Buy rating on the shares. The firm adjusted…
Caris Life Sciences price target raised to $35 from $23 at BofA
BofA raised the firm’s price target on Caris Life Sciences (CAI) to $35 from $23 and keeps a Buy rating on the shares as part of a specialty diagnostics group…
Caris Life Sciences initiated with a Neutral at UBS
UBS initiated coverage of Caris Life Sciences (CAI) with a Neutral rating and $28 price target The firm initiated and resumed 25 life science and diagnostics tools companies. UBS views…
Caris Life Sciences to present new research at IASCL 2026
Caris Life Sciences (CAI) announced that researchers from Caris and the Caris Precision Oncology Alliance will present seven studies at the International Association for the Study of Lung Cancer, IASL...
Caris Life Sciences price target raised to $33 from $32 at BTIG
BTIG raised the firm’s price target on Caris Life Sciences (CAI) to $33 from $32 and keeps a Buy rating on the shares.
Caris Life Sciences price target raised to $26 from $25 at Evercore ISI
Evercore ISI raised the firm’s price target on Caris Life Sciences (CAI) to $26 from $25 and keeps an Outperform rating on the shares.
Caris Life Sciences reports Q2 EPS 0c, consensus 1c
Reports Q2 revenue $263.7M, consensus $238.08M. “This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from inv...
Caris Life Sciences sees 2026 revenue $1.03B-$1.04B, consensus $”This was a reco
16:28 EDT Caris Life Sciences (CAI) sees 2026 revenue $1.03B-$1.04B, consensus $”This was a reco
Caris Life Sciences Earnings Call Transcript: Q2 2026
Record Q2 with 59,200 cases and 45% revenue growth, driven by commercial expansion and new product launches. Raised full-year guidance to $1.03–$1.04 billion, with continued investment in capacity and sales force. Strong demand for Caris Detect and robust financial position support ongoing innovation.
Caris Life Sciences Earnings release: Q2 2026
Caris Life Sciences released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Caris Life Sciences Slides: Q2 2026
Caris Life Sciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Caris Life Sciences Quarterly report: Q2 2026
Caris Life Sciences has published its Q2 2026 quarterly earnings report on August 5, 2026.